Search results
BioNTech SE to Post Q1 2024 Earnings of $1.26 Per Share, HC Wainwright Forecasts (NASDAQ:BNTX)
ETF DAILY NEWS· 7 days agoBioNTech SE (NASDAQ:BNTX – Free Report) – Stock analysts at HC Wainwright issued their Q1 2024 earnings per share (EPS) estimates for shares of
Moderna Faces Pfizer, BioNTech in London Patent Battle over Covid-19 Vaccines In Legal Showdown -...
Benzinga· 5 days agoModerna Inc. MRNA is set to clash with Pfizer Inc. PFE and BioNTech SE BNTX in a pivotal London...
Is Pfizer Stock A Sell As Shares Hit An 11-Year Low Amid The Search For Its Next Big Break?
Investor's Business Daily· 4 days agoPfizer stock is trading near an 11-year low as the drugmaker looks for its next big break after...
What's Going On With Pfizer Stock On Thursday? - GSK (NYSE:GSK), Pfizer (NYSE:PFE)
Benzinga· 3 days agoGSK Plc GSK has reportedly taken legal action against Pfizer Inc PFE and BioNTech SE BNTX in a...
The Cream Of The Crop: 5 Biotechs That Outrank Most Stocks
Investor's Business Daily· 3 days agoThe company is a leader in the neuroscience space. It recently dosed the first patient in a study of...
Wall Street plunges after US inflation shock
The Telegraph via Yahoo Finance· 3 days agoUS stock markets plunged amid fears of stagflation in the American economy, which grew at its slowest pace in nearly two years just as inflation jumped.
CureVac N.V. (CVAC) Q4 2023 Earnings Call Transcript
Seeking Alpha· 4 days agoCureVac N.V. (NASDAQ:NASDAQ:CVAC) Q4 2023 Earnings Conference Call April 24, 2024 9:00 AM ETCompany ParticipantsSarah Fakih - Vice President of Corporate...
CureVac to cut costs in restructuring
BioPharma Dive via Yahoo Finance· 4 days agoThe mRNA vaccine maker, which has lost most of its value since early 2021, is undergoing an “organizational redesign” that will eliminate 150 positions.
Xaira Therapeutics $1 billion funding round shows the excitement about AI drug discovery
Fortune· 3 days agoThe pursuit to use AI to discover new life-saving drugs got a big boost this week when a new company, Xaira Therapeutics, emerged from stealth with $1 billion in funding. The San Francisco-based ...